The soft tissue sarcoma market was valued at USD 3.69 Billion in 2025 and is expected to grow at a CAGR of 7.51%, reaching USD 7.61 Billion by 2035. The market growth is driven by increasing advancements in targeted therapies and immunotherapies, improving survival outcomes. Rising awareness, clinical trials, and government initiatives for rare cancers are further supporting the market. Continuous research collaboration, growing oncology investments, and emerging precision medicine approaches are anticipated to enhance market growth during the forecast period.
Base Year
Historical Period
Forecast Period
Compound Annual Growth Rate
7.51%
Value in USD Billion
2026-2035
*this image is indicative*
Soft tissue sarcoma is a cancer subtype that develops in soft tissues such as muscle, fat, tendons, and nerves. They represent 1% of all cancers that occur in adults . According to the American Cancer Society, 13,590 individuals will be diagnosed with soft tissue sarcoma in 2024, out of which 7,700 will be males and the rest 5,890 will be females. It is also predicted that it will cause mortality in 5,200 people. The growing number of patients with this rare type of cancer is expected to fuel the soft tissue sarcoma market growth.
The emergence of novel therapies to treat soft tissue sarcoma is also aiding the market growth. In the 2023 American Society of Clinical Oncology Annual Meeting, it was revealed that the combination of doxorubicin, balstilimab, and zalifrelimab demonstrated efficacy as well as favorable 6-month progression-free survival (PFS) rates in patients soft tissue sarcoma. The introduction of such treatment alternatives with manageable toxicity is anticipated to increase the soft tissue sarcoma market demand.
The market is projected to experience significant growth supported by the increasing adoption of targeted therapies along with the continued advancements in the drug pipelines throughout the forecast period. The rising healthcare expenditure and heightened patient awareness will also propel the market size.
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
The Expert Market Research report titled “Soft Tissue Sarcoma Market Report and Forecast 2026-2035” offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type:
Soft tissue sarcoma treatment includes radiation therapy, anti-angiogenesis agents, chemotherapy, targeted therapy, and other interventions. This segmentation outlines the range of therapeutic approaches employed to manage soft tissue sarcoma effectively with minimum adverse effects.
Market Breakup by Route of Administration:
Based on the route of administration, the soft tissue sarcoma market includes oral, parenteral, and others. In oral administration, medications are taken by mouth. Parenteral administration involves injections or infusions, to provide immediate therapeutic effect.
Market Breakup by End Users
The market segmentation by end users comprises hospitals, homecare, and specialty clinics, among others. Hospitals act as the primary centres for the diagnosis and treatment of soft tissue sarcoma patients.
Market Breakup by Distribution Channel
Distribution channels in the market include hospital pharmacies, retail pharmacies, and online pharmacies, among others. This distribution network enhances accessibility, catering to the diverse needs of the patients.
Market Breakup by Region
The market segmentation on a regional basis offers insights into the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. North America covers a significant portion of the market segment. This can be attributed to the rising prevalence of soft skin sarcoma and the growing demand for targeted therapies in the region.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Cardiovascular and Soft Tissue Repair Patches Market
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is anticipated to grow at a CAGR of 7.51% during the forecast period of 2026-2035, driven by the increasing number of cancer patients and demand for targeted therapies to treat soft tissue sarcoma across the 8 major markets.
The emergence of novel therapies to treat soft tissue sarcoma and the increased healthcare expenditure are fuelling the demand for the market.
One of the significant trends in the market is the rise in strategic partnerships among the key market players to address the growing demand of the market.
Based on the route of administration, the market includes oral, parenteral, and others.
Soft tissue sarcoma treatment includes radiation therapy, anti-angiogenesis agents, chemotherapy, targeted therapy, and others.
The market segmentation by end users comprises hospitals, homecare, and specialty clinics, among others.
Distribution channels in the market include hospital pharmacies, retail pharmacies, and online pharmacies, among others.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India.
Key players involved in the market are Endo International PLC, Dr. Reddy's Laboratories Ltd, Lupin, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Merck & Co., Lilly, Bayer AG, Novartis AG, GlaxoSmithKline PLC, Pfizer Inc, Sanofi, Teva Pharmaceutical Industries Ltd., Mylan N.V., and F. Hoffmann-La Roche Ltd.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by End Users |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share